Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
We've extended our forecasts out to 2028 and in our latest report, we take a look at what's in store for the medtech market in the next few years.
R&D pipelines are the lifeblood of the pharma industry - so why are we still getting it wrong?
The Evaluate Vantage team have hit the podcast studio again to discuss the good, the bad and the ugly of the pharma and medtech world
What were the highlights of ESC 2022?
The world is a long way from understanding the true and far-reaching legacy of Covid-19. While debate regarding the handling of the pandemic will continue, there are…
Natural language processing (NLP) is a key component of many machine learning approaches. We've looked at (broadly) how it works, now we investigate some of they key…
Machine learning and artificial intelligence are increasingly-used buzzwords in the pharma and biotech space. But what's hiding in that black box?
The market may be tough, but with unprecedented innovation taking place, there's plenty for biotechs and investors to feel positive about in the long term
Got time for a quick brain break? Listen to our podcast where we discuss the catalysts that will shape the third quarter of 2022.
Bio International was finally back for 2022. What did our first-timer to the event make of it?